ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
37 announcements with these filters
Roshan Dealmark Private Limited (Promoter Group) sold 700,000 equity shares of Tavexia Lifecare Ltd via market sale on September 25, 2026.
Promoter Group entity, Roshan Dealmark Private Limited, sold 2,00,000 shares of Tavexia Lifecare Ltd in the open market, aggregating to ₹0.02 Crore.
Promoter group entity Roshan Dealership Private Limited sold 4,00,000 Tavexia Lifecare shares on BSE for ₹0.05 Crore. Stake reduced from 4.03% to 3.93%.
Promoter Roshan Dealmark Pvt Ltd sold 4,00,000 Tavexia Lifecare shares on-market on 23.09.2026. Its stake fell from 4.051% to 3.947%, a 0.104% reduction.
Roshan Dealmark, a promoter group entity, sold 9,07,105 shares of Tavexia Lifecare on BSE for Rs. 0.11 Crore. Stake reduced from 4.27% to 4.03%.
Roshan Dealmark Private Limited (Promoter Group) sold 2,80,000 equity shares of Tavexia Lifecare Ltd through a market sale on the BSE. The transaction value was ₹0.03 Crore.
Roshan Dealmark Private Limited, part of the Promoter Group, sold 10 lakh shares of Tavexia Lifecare Ltd for ₹0.12 Crore via market sale.
Promoter Group entity Roshan Dealmark Private Limited sold 8,01,878 equity shares of Tavexia Lifecare Ltd via market sale on BSE, reducing its stake by 0.21%.
Roshan Dealmark, a promoter, disposed 14,00,000 Tavexia Lifecare shares on-market on 15 Sep 2026, cutting its stake from 5.19% to 4.83%.
Promoter group entity Roshan Dealmark sold 18 lakh shares of Tavexia Lifecare via market sale. The sale reduces the promoter's stake by 0.47%.
Roshan Dealmark Private Limited (Promoter Group) sold 14,00,000 equity shares of Tavexia Lifecare Ltd for ₹0.16 Crore via an open market transaction.
Tavexia Lifecare Limited has submitted its 46th Annual Report for the Financial Year 2025-2026, which includes the notice for the upcoming Annual General Meeting.
Tavexia Lifecare Limited announced the closure of its register of members from September 24 to September 30, 2026, for the 46th Annual General Meeting.
Tavexia Lifecare announced board meeting outcomes, including statutory auditor changes, independent director reappointment, and a proposal to explore acquiring a 60% stake in Meyonex Pharmaceuticals.
Tavexia Lifecare Limited announced the resignation of its statutory auditor, M/s. SSRV and Associates, effective September 7, 2026, due to professional and administrative reasons.
Promoter Roshan Dealmark disposed 14,00,000 Tavexia Lifecare shares in the open market. Its stake fell from 6.39% to 6.02%, a 0.36% reduction.
Roshan Dealmark Private Limited, a promoter group entity, sold 14,00,000 equity shares of Tavexia Lifecare Ltd via market sale. The transaction value is Rs. 14 Lakhs.
Tavexia Lifecare Limited scheduled a board meeting for September 4th, 2026, to discuss director reappointment, related party transaction limits, and the upcoming 46th Annual General Meeting.
Tavexia Lifecare has entered the pharmaceutical sector as a new growth vertical, aiming to diversify its revenue base and build a broader healthcare platform.
Sattva Sukun Lifecare Limited has officially changed its name to Tavexia Lifecare Limited, effective August 14, 2026, following approval from the Ministry of Corporate Affairs.
Sattva Sukun Lifecare Ltd reported revenue from operations of ₹0.6 Cr (-50.0% YoY) and a net loss of ₹0.2 Cr for Q1 FY27.
Sattva Sukun Lifecare Limited will hold a Board meeting on August 4, 2026, to consider quarterly financial results and usage of proceeds from its rights issue.
Sattva Sukun Lifecare Limited concluded its Extraordinary General Meeting (EOGM) held on July 22, 2026. The meeting covered resolutions regarding director appointments and company name change.
Sattva Sukun Lifecare approved a corrigendum to its EOGM notice for a proposed name change to Tavexia Lifecare Limited. The change aligns with new branding strategies.
Sattva Sukun Lifecare scheduled an EOGM for July 22, 2026. Agenda includes director appointments and changing the company name to Tavexia Lifecare Limited.
Sattva Sukun Lifecare Ltd announced its board meeting outcomes on 30 June 2026, approving director appointments and a name change. No dividend, fund raise or results were disclosed.
Sattva Sukun Lifecare scheduled a board meeting for June 29, 2026. The agenda includes director regularizations and memorandum alterations.
Sattva Sukun Lifecare Ltd reported revenue from operations of ₹8.5 Cr (+672.7% YoY) and a net loss of ₹0.7 Cr for Q4 FY26.
Sattva Sukun Lifecare postponed its board meeting from May 30 to June 4, 2026. The delay is attributed to the ongoing audit process for FY26 financial results.
Sattva Sukun Lifecare Limited submitted its Revised Annual Secretarial Compliance Report for FY2025-26. The revision addresses delays in financial results submission and ongoing website technical issues.